Imago BioSciences Raises $80 Million in Series C Financing

Nov 19, 2020•about 5 years ago

Amount Raised

$80 Million

Round Type

series c

San Francisco

Description

Imago BioSciences, Inc. (“Imago”), a clinical-stage biopharmaceutical company developing innovative treatments for myeloproliferative neoplasms, today announced the close of an $80 million Series C financing round. Farallon Capital Management, LLC led the round, with participation from new investors including funds and accounts advised by T. Rowe Price Associates, Inc., funds and accounts managed by Blackrock Advisors, LLC., Surveyor Capital (a Citadel company), Irving Investors and Kingdon Capital Management

Company Information

Company

Bomedemstat

Location

San Francisco, California, United States

About

Bomedemstat is being evaluated in open-label Phase 2 clinical trials for the treatment of advanced myelofibrosis (MF), essential thrombocythemia (ET) and polycythemia vera, bone marrow cancers that alter the production of blood cells. MF patients who are resistant to, intolerant of, or ineligible for a Janus Kinase (JAK) inhibitor are eligible for the study of bomedemstat as monotherapy. Interim data will be presented in an oral session at the upcoming American Society of Hematology Annual Congress on December 5, 2020.

Related People

2 contacts

Funding Insights

Based on industry data

Tech investment trends

83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech

Imago BioSciences Raises $80 Million in Series C Financing

Description

.css-1v6jzuu{--tw-text-opacity:1;color:rgba(75, 85, 99, var(--tw-text-opacity));}Company Information

Related People

Funding Insights

Company Information